Community - Public Portfolios & Trending Stocks | AllInvestView

Earnings Recaps

Browse reported earnings of the most popular stocks

May 16, 2026 May 15, 2026 May 14, 2026 May 13, 2026 May 12, 2026 May 11, 2026 May 10, 2026 May 9, 2026 May 8, 2026 May 7, 2026 May 6, 2026 May 5, 2026 May 4, 2026 May 3, 2026 May 2, 2026 May 1, 2026 Apr 30, 2026 Apr 29, 2026 Apr 23, 2026 Apr 22, 2026 Apr 21, 2026 Apr 20, 2026 Apr 18, 2026 Apr 17, 2026 Apr 16, 2026 Apr 15, 2026 Apr 14, 2026 Apr 13, 2026 Apr 10, 2026 Apr 9, 2026 Apr 8, 2026 Apr 7, 2026 Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026 Mar 2, 2026 Feb 28, 2026 Feb 27, 2026 Feb 26, 2026 Feb 25, 2026 Feb 24, 2026 Feb 23, 2026 Feb 21, 2026 Feb 20, 2026 Feb 19, 2026 Feb 18, 2026 Feb 17, 2026 Feb 14, 2026 Feb 13, 2026 Feb 12, 2026 Feb 11, 2026 Feb 10, 2026 Feb 9, 2026 Feb 7, 2026 Feb 6, 2026 Feb 5, 2026 Feb 4, 2026 Feb 3, 2026 Feb 2, 2026 Jan 31, 2026 Jan 30, 2026 Jan 29, 2026 Jan 28, 2026 Jan 27, 2026 Jan 26, 2026 Jan 23, 2026 Jan 22, 2026 Jan 21, 2026 Jan 20, 2026 Jan 17, 2026 Jan 16, 2026 Jan 15, 2026 Jan 14, 2026 Jan 9, 2026 Jan 8, 2026 Jan 7, 2026 Jan 6, 2026 Dec 19, 2025 Dec 18, 2025 Dec 17, 2025 Dec 12, 2025 Dec 11, 2025 Dec 10, 2025 Dec 9, 2025 Dec 6, 2025 Dec 5, 2025 Dec 4, 2025 Dec 3, 2025 Dec 2, 2025 Dec 1, 2025 Nov 27, 2025 Nov 26, 2025 Nov 25, 2025 Nov 24, 2025 Nov 23, 2025 Nov 21, 2025 Nov 20, 2025 Nov 19, 2025 Nov 18, 2025 Nov 17, 2025 Nov 15, 2025 Nov 14, 2025 Nov 13, 2025 Nov 12, 2025 Nov 11, 2025 Nov 10, 2025 Nov 9, 2025 Nov 8, 2025 Nov 7, 2025 Nov 6, 2025 Nov 5, 2025 Nov 4, 2025 Nov 1, 2025 Oct 31, 2025 Oct 30, 2025 Oct 29, 2025 Oct 28, 2025 Oct 27, 2025 Oct 25, 2025 Oct 24, 2025 Oct 23, 2025 Oct 22, 2025 Oct 21, 2025 Oct 17, 2025 Oct 16, 2025 Oct 15, 2025 Oct 14, 2025 Oct 9, 2025 Oct 8, 2025 Oct 7, 2025 Sep 25, 2025 Sep 23, 2025 Sep 17, 2025 Sep 16, 2025 Sep 11, 2025 Sep 10, 2025 Sep 9, 2025 Sep 5, 2025 Sep 4, 2025 Sep 3, 2025

24 companies Today

Airbnb, Inc.

ABNB Q1 2026

Reported: 2026-05-10

Airbnb's shares rose modestly by 1.2% following Q1 results that showed solid top-line growth and continued product innovation but lacked a strong catalyst to push the stock higher. While demand trends remain healthy, the market appears cautious, possibly due to limited commentary on margin expansion or outlook specifics.

Key takeaways

Revenue grew 18% year-over-year to $2.7 billion, surpassing the high end of guidance.
Gross booking value increased 19% year-over-year, supported by pricing strength and resilient demand despite a 100 bps headwind from geopolitical tensions.
Nights and seats booked rose 9%, with app nights booked up 22% and first-time bookers accelerating 10%, led by growth in Brazil, Japan, and India.
New features like Reserve Now, Pay Later contributed ~20% of global GBV, shifting booking patterns toward longer lead times and higher-end homes.
AI integration improved engineering productivity and helped resolve over 40% of customer support issues without human intervention, signaling operational efficiency gains.

Ameren Corporation

AEE Q1 2026

Reported: 2026-05-10

Ameren shares declined 2.6% after the quarter, reflecting investor caution despite steady execution, as the company did not update its sales growth forecast or materially advance large-load electric demand visibility, leaving growth drivers uncertain.

Key takeaways

Q1 earnings rose to $1.28 per share from $1.07 year-over-year, driven by infrastructure investments aimed at long-term benefits.
Reaffirmed 2026 EPS guidance at $5.25 to $5.45 with no upward revision despite ongoing investments.
Infrastructure investments totaled over $1.5 billion in Q1, enhancing grid reliability and reducing customer outages during severe weather events.
Large-load demand via energy service agreements (ESAs) remains a growth opportunity but progress towards updating the sales forecast tied to these remains pending.
Continued focus on cost allocation to large customers and maintaining a balanced generation portfolio amid an evolving demand base.

Affirm Holdings, Inc.

AFRM Q3 2026

Reported: 2026-05-10

Affirm's stock declined 2.4% after reporting fiscal Q3 results that showed stable credit performance and constructive funding markets but lacked clear drivers to excite investors or alter the cautious outlook.

Key takeaways

Credit quality remained stable with no signs of deterioration in Affirm’s underwritten consumer base.
Funding conditions remained exceptionally constructive, with multiple oversubscribed deals and tightening spreads leading to a 125 basis point reduction in funding costs year-over-year.
The company highlighted improved marketing efficiency and targeting for its upcoming promotional event but provided no new guidance or metrics that shifted the outlook.
No indication of margin expansion or revenue acceleration was evident from management commentary despite references to ongoing "record" performance.
The market reaction suggests investors see limited upside given the stable but unremarkable quarter and cautious forward commentary.

American Healthcare REIT, Inc.

AHR Q1 2026

Reported: 2026-05-10

The market reacted positively, with a 4.3% stock increase, signaling investor approval of American Healthcare REIT's raised full-year guidance and sustained double-digit same-store NOI growth amidst a favorable operating environment.

Key takeaways

Same-store NOI grew 12.1% for the ninth consecutive quarter, highlighting consistent operational momentum.
ISHC (Trilogy) segment led with 14.5% same-store NOI growth and occupancy rising to 91.2%, up 220 basis points year-over-year.
Same-store revenue increased 6.9%, driven by both rate and occupancy improvements.
Quality mix improved to 75.5% of resident days on a same-store basis, reflecting a strategic focus on Medicare Advantage alignments.
Management raised 2026 guidance, supported by disciplined capital deployment and a strengthened balance sheet.

BCP Investment Corp.

BCIC Q1 2026

Reported: 2026-05-10

BCP Investment Corporation’s shares rose 6.2% following Q1 results, reflecting investor approval of accretive share repurchases, income growth, and improved credit metrics despite ongoing portfolio markdowns driven by software and AI-sector valuation pressures.

Key takeaways

Net investment income grew to $6.9 million ($0.55 per share), exceeding the base distribution and supporting a supplemental distribution declaration of $0.03 per share for Q2.
Nonaccruals improved, declining to 6.2% of the portfolio from 7.1%, with the number of nonaccrual companies reducing to nine from ten.
The company repurchased shares in 2026, boosting NAV per share by $0.07 and supporting a transition to monthly dividends with a steady Q3 base distribution of $0.27 per share.
Net asset value declined during the quarter due primarily to unrealized markdowns concentrated in software and AI-exposed investments, many in illiquid, non-publicly quoted securities.
Liability management actions, including issuing $50 million of 7% notes due 2029 and redeeming $40 million of near-term debt, enhanced financial flexibility and extended maturity profiles.

Cognex Corporation

CGNX Q1 2026

Reported: 2026-05-10

Cognex shares rose 5.5% after Q1 results that delivered double-digit revenue growth and significant margin expansion, driven by strong demand in semiconductor, logistics, and packaging end markets as well as successful product launches that exceeded expectations.

Key takeaways

Revenue, adjusted EBITDA, and adjusted EPS each posted double-digit year-over-year growth, surpassing guidance and consensus.
Adjusted EBITDA margin expanded by over 1,000 basis points year-over-year to 26.9%, marking the seventh consecutive quarter of margin improvement.
Broad-based demand was led by semiconductor, electronics, packaging, and logistics end markets, with semiconductor revenue growth notably strong across Asia.
Launched two new embedded AI vision systems (In-Sight 6900 and 3900), strengthening leadership in AI-powered machine vision and supporting future growth potential.
Cost reduction efforts remain on track to deliver $35 million to $40 million in net savings, supporting durable margin expansion.

Clean Energy Fuels Corp.

CLNE Q1 2026

Reported: 2026-05-10

Shares of Clean Energy Fuels Corp. declined 1.3% following Q1 results as operational execution in RNG production remains uneven and adoption in the key Class 8 trucking segment is slower than anticipated, tempering upside despite rising diesel prices.

Key takeaways

Delivered 67 million gallons of renewable natural gas (RNG) and generated $16.6 million of Adjusted EBITDA in the quarter.
Trucking, the largest growth opportunity, underperformed expectations due to slow adoption of Cummins X15N engines amid regulatory uncertainty and high upfront costs.
RNG production ramp-up faced headwinds from extreme winter weather and operational challenges at several projects, delaying expected improvements.
Management is taking a more hands-on operational approach, replacing vendors and strengthening oversight to address production inefficiencies.
Positive regulatory development with CARB approval of a low carbon intensity pathway (~ -300) for the Del Rio Dairy project, though credits awaiting updated federal valuation remain a key variable.

CIM Commercial Trust Corporation

CMCT Q1 2026

Reported: 2026-05-10

Shares dropped 8% following the quarter as investors reacted negatively to a cautious outlook and limited near-term impact from recent balance sheet improvements, alongside ongoing operating challenges in office and hotel segments.

Key takeaways

Redeemed $243 million of preferred stock, improving balance sheet and expected to add $16 million annually to FFO starting Q2, but minimal impact reflected in Q1 results.
Multifamily NOI rose 64% excluding JV properties, with occupancy improving 940 bps year-over-year to 89.6%, showing early signs of recovery in Oakland.
Office NOI declined by $600,000 year-over-year, impacted by a prior-year tax appeal benefit and vacancy remaining elevated outside of Oakland assets.
Hotel NOI dropped $700,000 due to renovation disruptions and mechanical issues temporarily reducing available rooms, though renovations are now mostly complete.
The company remains focused on refinancing debt maturities and selective asset sales but signaled a cautious outlook, which likely weighed on investor sentiment.

Charles River Laboratories International, Inc.

CRL Q1 2026

Reported: 2026-05-10

Charles River’s shares declined 2.3% following the Q1 earnings, reflecting investor caution amid ongoing portfolio restructuring and a cautious outlook on margin expansion despite announced cost savings and strategic divestitures.

Key takeaways

Delivered $100 million in incremental cost savings this year above 2025 levels, targeting $300 million in annualized savings from recent initiatives.
Completed acquisitions to secure non-human primates supply and enhance next-generation sequencing capabilities supporting biologics testing.
Divested CDMO and Cell Solutions businesses, with additional European discovery site sales planned, focusing on core drug development testing strengths.
Initiatives expected to contribute to future margin expansion, though near-term performance and guidance left the market hesitant.

Fluence Energy, Inc.

FLNC Q2 2026

Reported: 2026-05-10

Fluence Energy’s stock surged 78.2% on the heels of strong order intake momentum and an improving margin profile, signaling investor confidence in the company’s ability to capitalize on expanding demand and new customer wins despite some supply headwinds.

Key takeaways

Year-to-date order intake reached approximately $2 billion, doubling the total from the same period last fiscal year, with a record backlog of $5.6 billion at quarter-end.
Adjusted gross margin improved to 11.1% in Q2, aligning well within the targeted 11% to 13% full-year range, reflecting more disciplined execution.
Fluence reaffirmed fiscal 2026 guidance for revenue, annual recurring revenue (ARR), and adjusted EBITDA, indicating stable outlook despite earlier challenges.
New customer acquisition accelerated, with 50% of orders from new customers and strategic master supply agreements secured with two major hyperscalers.
Supply chain constraints due to lithium price fluctuations slowed some deals temporarily but stabilized during the quarter, resuming order momentum.

Fidelity National Financial, Inc.

FNF Q1 2026

Reported: 2026-05-10

Shares declined 1.4% following the quarter, reflecting investor caution despite stable volume trends due to lack of clear margin expansion or uplift in guidance.

Key takeaways

Adjusted pre-tax Title earnings increased 27% year-over-year to $268 million, with a margin expansion of 140 basis points to 13.1%.
Purchase orders showed modest growth, with daily orders improving sequentially and a 7% year-over-year increase in total orders opened for April (6,200 per day).
Refinance orders rose strongly on lower mortgage rates early in the quarter but moderated in April as rates increased again.
Direct commercial revenue grew 15% year-over-year to $338 million, driven by 22% growth in national revenues and 8% in local revenues.
Management reaffirmed confidence in maintaining 15%-20% annual Title margins, but caution around near-term residential volume stability and mortgage rate fluctuations persists.

GoodRx Holdings, Inc.

GDRX Q1 2026

Reported: 2026-05-10

GoodRx shares edged up 2.8% post-earnings, reflecting a generally steady reaction to solid growth in Pharma Direct and broader platform engagement but without a clear breakout catalyst to push the stock higher.

Key takeaways

Pharma Direct revenue surged 82% year-over-year, fueled by manufacturer-sponsored pricing programs and strong uptake of new GLP-1 therapies such as Wegovy Pill and Ozempic Pill.
GoodRx accounted for roughly one-third of Wegovy Pill transactions in the first two months post-launch, underscoring its growing influence in the self-pay prescription market.
The company expanded manufacturer collaborations, including a new program with Viatris for 17 brand medications and a Pfizer-branded storefront offering discounts on 30+ essential drugs.
Rx Marketplace performance aligned with internal expectations, supported by ongoing e-commerce expansion and direct contracting models.
Management highlighted evolving healthcare dynamics—widening coverage gaps and elevated out-of-pocket costs—that continue to validate GoodRx’s strategy of improving affordability and access.

Himax Technologies, Inc.

HIMX Q1 2026

Reported: 2026-05-10

Himax’s shares surged 44.3% on the quarter as profits and margins came in at the high end of guidance, driven by better-than-expected restocking in the large display driver segment and initial success in new OLED smartphone ICs.

Key takeaways

Q1 revenue declined slightly by 2.0% sequentially to $199.0 million but remained at the high end of guidance; gross margin held steady at 30.4%, also at the top of the guided range.
Operating profit rose sequentially to $10.2 million (5.1% margin) on lower expenses but declined year-over-year due to softer sales and higher operating costs.
Large display driver revenue grew 11.7% sequentially, fueled by unexpected restocking from a leading panel maker, increasing its revenue share to 12.2%.
Small/medium display driver sales dipped 2.4%, reflecting seasonality despite gains in smartphone and tablet IC shipments, supported by new OLED solutions entering production.
Automotive driver sales fell double digits sequentially due to seasonality, inventory controls, and subsidy reductions; however, non-driver automotive business shows strong design-win momentum with future ramp-up potential.

Intrepid Potash, Inc.

IPI Q1 2026

Reported: 2026-05-10

Intrepid Potash reported a broadly steady first quarter with solid pricing and volume contributing to improved profitability, but the market closed up only 0.4%, reflecting tempered investor enthusiasm amid no clear upside surprises.

Key takeaways

Adjusted net income was $8.2 million, up from $3.9 million in Q1 2025, with adjusted EBITDA increasing to $19 million from $14.6 million.
Average potash net realized sales price rose 13% year over year to $353 per ton; Trio prices increased 12% to $387 per ton.
Combined sales volumes of potash and Trio reached 211,000 tons, marking the second-highest quarterly total since 2016.
Operational efficiencies improved, with a 5% reduction in per-ton costs compared to Q4 and Trio delivering its highest segment margin since 2022.
The sale of Intrepid South Ranch for $70 million provided a significant cash inflow and focus on fertilizer assets, while lithium project progress continues without material updates on economics.

Lantheus Holdings, Inc.

LNTH Q1 2026

Reported: 2026-05-10

Lantheus’ shares rose 8.0% following a quarter marked by better-than-expected commercial execution and meaningful regulatory progress, supporting confidence in the company’s focused radio diagnostics strategy and growth trajectory.

Key takeaways

PYLARIFY U.S. volumes grew approximately 5.8% year-over-year, holding stable net ASPs despite competitive pressures.
FDA approval of PYLARIFY TRUVU, a manufacturing-optimized formulation, positions Lantheus to increase supply and geographic reach starting in Q4.
Positive regulatory developments include tentative FDA approval for PNT2003 (radio equivalent to Lutathera) and upcoming PDUFA for MK-6240, a tau-targeted PET diagnostic slated for August.
Continued focus on commercial execution in oncology, neurology, and cardiology drove solid volume growth across core products.
The CEO search advances with strong internal alignment to maintain disciplined capital allocation and long-term pipeline prioritization.

PennantPark Floating Rate Capital Ltd.

PFLT Q2 2026

Reported: 2026-05-10

PennantPark Floating Rate Capital's shares declined modestly by 0.6% following the quarter, reflecting investor caution amid the updated dividend framework and a tempered outlook on dividend growth despite stable portfolio metrics.

Key takeaways

Core net investment income was $0.27 per share for the quarter ended March 31.
The company updated its dividend framework, setting a new base monthly dividend of $0.08 per share with a variable supplemental dividend tied to excess net investment income.
Portfolio remained stable with NAV flat quarter-over-quarter; nonaccruals were low at 0.8% of cost and 0.5% of market value.
Investment activity remained substantial, with $295 million deployed at a weighted average yield of 9.3%; portfolio leverage and coverage metrics remained conservative.
Positive driver included expected realization of equity co-investment in Echelon, forecast to generate approximately $47 million in proceeds.

PPL Corporation

PPL Q1 2026

Reported: 2026-05-10

Shares declined 2.3% following the earnings release, reflecting investor caution despite reaffirmed guidance and ongoing operational progress, likely due to concerns over regulatory uncertainties and limited near-term growth catalysts.

Key takeaways

Reported first quarter GAAP EPS was $0.60, with adjusted ongoing EPS of $0.63, consistent with expectations.
Reaffirmed 2026 ongoing earnings guidance of $1.90 to $1.98 per share, maintaining the midpoint at $1.94.
Completed a constructive distribution base rate settlement in Pennsylvania, with less than 4% bill increases and a two-year stay-out.
Regulatory risks remain in Kentucky, with ongoing reconsideration of base rate case decisions potentially delaying rate adjustments.
Announced exploratory partnerships for innovative generation projects, including pumped storage hydro and small modular nuclear reactors, though these have no current impact on capital plans or near-term earnings.

SandRidge Energy, Inc.

SD Q1 2026

Reported: 2026-05-10

SandRidge’s shares declined modestly by 0.4% following Q1 results that were largely inline with expectations, showing steady production growth and margin improvements but no significant positive catalyst to drive the stock higher.

Key takeaways

Production increased 4% year-over-year to 18.6 MBOE per day, with oil production up 31%, supporting a 17% revenue increase versus Q1 2025.
Adjusted EBITDA rose to $33.7 million from $25.5 million last year; adjusted G&A expenses improved on a per BOE basis to $1.42 from $1.83.
Cash flow from operations was stable at $19.8 million versus $20.3 million a year ago, though adjusted operating cash flow increased to $34.4 million.
The company completed three wells and brought two online in the quarter, maintaining a disciplined capital spend of $19.9 million, within expectations.
Dividend payments increased with an 8% raise in the regular dividend plus a one-time special dividend, reflecting shareholder return focus despite limited market enthusiasm.

Skyward Specialty Insurance Group Inc. Common Stock

SKWD Q1 2026

Reported: 2026-05-10

Shares rose 6.5% following results that showcased better-than-expected earnings momentum and premium growth, driven by the Apollo acquisition and strong operating performance across segments.

Key takeaways

Diluted operating EPS reached $1.25, up 39% year over year, reflecting combined company synergies and accretion from Apollo.
Gross written premiums grew 10% on a pro forma basis, with managed premiums up 20%, including a 49% increase in fee-generating premiums to $300 million.
Skyward Specialty’s combined ratio improved to 88.9 (86.8 ex-cat), while Apollo delivered an 85.3 combined ratio with no catastrophe losses this quarter.
Annualized operating return on equity stood at 20.3%, underscoring robust earnings power.
Net investment income increased by $7.5 million year over year to $27 million, supported by a $2.7 billion invested portfolio dominated by fixed income.

US Foods Holding Corp.

USFD Q1 2026

Reported: 2026-05-10

US Foods shares dropped 8.3% post-earnings, reflecting investor disappointment primarily driven by a cautious outlook amid challenging macro conditions and weather disruptions, which overshadowed top-line growth and margin gains.

Key takeaways

Despite severe weather and geopolitical uncertainty, the company reported 4.4% organic independent restaurant case growth, its strongest in two years.
Adjusted diluted EPS grew 15%, supported by 6% adjusted EBITDA growth and gross profit rising faster than operating expenses.
Distribution center closures due to winter storms nearly doubled compared to last year, negatively impacting operational performance.
The company highlighted strong progress in safety, reducing injury rates by 12% year-over-year and investing in digital tools like MenuIQ, adopted by 15% of independent customers within two months.
Market reaction indicates skepticism about the outlook and the external headwinds despite execution efforts and case growth momentum.

Vir Biotechnology, Inc.

VIR Q1 2026

Reported: 2026-05-10

Shares dropped 11.4% following Q1 results as investors reacted negatively to cautious outlook and underwhelming financial updates despite clinical progress, signaling disappointment with the company's near-term prospects and margin pressures.

Key takeaways

Collaboration with Astellas on VIR-5500 in prostate cancer advanced, with deal closure and joint clinical plans underway.
Phase I data showed a favorable safety profile for VIR-5500, notably no Grade 3 cytokine release syndrome and potential outpatient administration benefits.
Early signs of durable responses observed in heavily pretreated metastatic castration-resistant prostate cancer (MCRPC) patients, including some with liver metastases.
Dose escalation ongoing with expansion cohorts addressing both RLT-naive and post-RLT patient populations, plus early-line combination trials starting soon.
Financial commentary indicated concerns around guidance and margin trends, which were the likely drivers of the negative investor reaction despite clinical updates.

XPLR Infrastructure, LP

XIFR Q1 2026

Reported: 2026-05-10

XPLR Infrastructure's stock ticked up modestly by 2.8% following its Q1 2026 results, reflecting a largely in-line performance with some offsetting factors including seasonally lower wind resources and higher financing costs weighing on free cash flow.

Key takeaways

Adjusted EBITDA for Q1 2026 was approximately $435 million with Free Cash Flow Before Growth of $89 million, reflecting typical seasonal patterns and finance cost impacts.
Wind generation came in at 99% of the long-term average, down from 103% in Q1 last year, partially offset by positive contributions from ongoing repowering initiatives (30% complete).
Incremental corporate interest expense increased by about $74 million due to $1.75 billion of unsecured notes issued in March 2025, plus $12 million higher project-level interest expense, pressuring free cash flow.
Higher year-over-year O&M costs occurred as a result of accelerated major component work and lower wind resource impacts.
The company reaffirmed full-year 2026 guidance for adjusted EBITDA between $1.75 billion and $1.95 billion and Free Cash Flow Before Growth between $600 million and $700 million, assuming normal weather conditions.

Xometry Inc. Class A Common Stock

XMTR Q1 2026

Reported: 2026-05-10

Xometry's shares gained 1.9% following Q1 results that showed continued growth acceleration and improving margins, though the market reaction suggests the quarter met expectations without significant upside or downside surprises.

Key takeaways

Revenue growth accelerated to 36% year-over-year, a 600 basis point improvement from Q4, driven largely by 40% growth in the Marketplace segment.
Adjusted EBITDA rose to $10.5 million, up $10.4 million year-over-year, reflecting expanding margins alongside faster growth.
Active buyers increased 20% year-over-year, supporting broad-based marketplace strength and ongoing customer expansion.
Announced a $50 million investment from Siemens as part of a strategic partnership to integrate Xometry’s AI capabilities into Siemens’ design ecosystem, enhancing upstream market penetration.
Management remains confident in continued robust growth throughout 2026, with a sustained focus on embedding AI-driven intelligence to streamline manufacturing procurement workflows.

Zymeworks Inc.

ZYME Q1 2026

Reported: 2026-05-10

Zymeworks shares were unchanged following the quarter, reflecting investor indifference to a steep revenue decline offset by modest improvements in expenses and advancing pipeline updates, while the widening net loss and reduced milestone income raised concerns.

Key takeaways

Revenue fell sharply to $2.4 million from $27.1 million year-over-year, primarily due to the absence of nonrecurring clinical milestone payments received in Q1 2025.
Operating expenses decreased modestly to $49.5 million from $52.7 million, driven by lower R&D spend on late-stage and discontinued programs but partly offset by increased early-stage investment and leadership transition costs.
Net loss widened to $44.2 million from $22.6 million in the prior year quarter, reflecting the revenue drop and ongoing investment in development activities.
Advances in the pipeline include progressing regulatory and commercial milestones for zanidatamab and initial positive early-stage clinical data for ADC candidates presented at AACR.
Management emphasized a strategic focus on integrating R&D with royalty aggregation but did not provide updated financial guidance or concrete near-term revenue visibility beyond milestone expectations.

Community

See what investors are trading, holding, and sharing

🌐

📈

📊

🏦

🪙

💱

#	Asset	Price	Community %	Type	Currency	Sector

2026 © AllInvestView

Twitter YouTube Reddit Feature Requests Support Pricing Help

Support email: [email protected]

Terms of Service | Privacy Policy

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.